What AVANIR PHARMACEUTICALS, INC.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Ocampo Christine | Vice President, Finance | Dec 18 | Open-market sale · S | −5,780 | $16.93 | −$97.9K | 108,797 |
| Siffert Joao Md | SVP, R&D | Dec 18 | Open-market sale · S | −15,505 | $16.93 | −$262K | 314,192 |
| Siffert Joao Md | SVP, R&D | Dec 18 | Withheld — tax / exercise cost · F | −19,204 | $16.99 | −$326K | 329,697 |
| Siffert Joao Md | SVP, R&D | Dec 18 | Exercise / conversion · M | +32,291 | $2.59 | +$83.6K | 348,901 |
| Katkin Keith | President and CEO | Dec 17 | Open-market sale · S | −62,520 | $16.93 | −$1.06M | 914,249 |
| Ocampo Christine | Vice President, Finance | Dec 16 | Open-market sale · S | −17,500 | $16.94 | −$296K | 114,577 |
| Ocampo Christine | Vice President, Finance | Dec 16 | Open-market sale · S | −12,500 | $16.94 | −$212K | 132,077 |
| Ocampo Christine | Vice President, Finance | Dec 16 | Exercise / conversion · M | +17,500 | $4.18 | +$73.2K | 144,577 |
| Ocampo Christine | Vice President, Finance | Dec 16 | Exercise / conversion · M | +12,500 | $2.59 | +$32.4K | 127,077 |
| Katkin Keith | President and CEO | Dec 15 | Open-market sale · S | −195,160 | $16.95 | −$3.31M | 976,769 |
| Katkin Keith | President and CEO | Dec 15 | Exercise / conversion · M | +55,960 | $1.29 | +$72.2K | 1,171,929 |
| Katkin Keith | President and CEO | Dec 15 | Exercise / conversion · M | +139,200 | $1.74 | +$242K | 1,115,969 |
| Katkin Keith | President and CEO | Dec 15 | Open-market sale · S | −20,000 | $16.95 | −$339K | 976,769 |
| Palekar Rohan | SVP & Chief Commercial Officer | Nov 28 | Open-market sale · S | −15,000 | $15.00 | −$225K | 302,806 |
| Katkin Keith | President and CEO | Nov 10 | Grant / award · A | +140,611 | — | — | 996,769 |
| Katkin Keith | President and CEO | Nov 10 | Grant / award · A | +220,563 | — | — | 856,158 |
| Ocampo Christine | Vice President, Finance | Nov 10 | Grant / award · A | +19,844 | — | — | 114,577 |
| Ocampo Christine | Vice President, Finance | Nov 10 | Grant / award · A | +31,992 | — | — | 94,733 |
| Siffert Joao Md | SVP, R&D | Nov 10 | Grant / award · A | +34,825 | — | — | 316,610 |
| Siffert Joao Md | SVP, R&D | Nov 10 | Grant / award · A | +59,231 | — | — | 281,785 |
Loading...
